Status:
RECRUITING
Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Pancreatic Adenocarcinoma
Weight Loss
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection ...
Detailed Description
Small intestinal bacterial overgrowth syndrome (SIBO) is a condition defined by excessive (greater than 105 CFU/mL) or abnormal bacteria in the upper gastrointestinal tract resulting in unintentional ...
Eligibility Criteria
Inclusion
- Men, Women, and all genders
- Individuals 18 years old or older are included.
- Patients of the study investigators and team members
- Diagnosis of pancreatic ductal adenocarcinoma
- All subjects must consent to this study
- Clinically diagnosed weight loss
Exclusion
- Minors
- Pregnant Women
- Any records flagged "break the glass" or "research opt out."
- Patients who have received treatment for SIBO in the past 3 months
Key Trial Info
Start Date :
April 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 14 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06988150
Start Date
April 14 2025
End Date
April 14 2026
Last Update
May 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048